Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Progestogen-only contraceptive (POP + emergency contraception)

Updated · Methodology

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list oral contraceptives among the drugs that can reduce its anticoagulant effect, without giving a mechanism (acenocoumarol SmPCs, AEMPS). In Spain, levonorgestrel tablets without an oestrogen are available only for emergency contraception, as a single 1.5 mg tablet by mouth. Their SmPCs call this oral emergency contraception (levonorgestrel SmPCs, AEMPS). The documents contain no study of this pair. According to the levonorgestrel SmPC, no significant changes in clotting factors are expected at the recommended dose (levonorgestrel SmPC, AEMPS).

Symptoms

According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After a 1.5 mg levonorgestrel tablet, heavy periods and bleeding are very common. Spotting and irregular bleeding have been reported in up to 30% of women until the next period. Post-marketing reports include isolated thromboembolic events (levonorgestrel SmPC, AEMPS). Uterine bleeding is also among the signs of excess acenocoumarol, together with bleeding into the skin, blood in the urine, bruising, and gastrointestinal, nose and gum bleeding (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated. The acenocoumarol summary of product characteristics (SmPC) lists oral contraceptives among the drugs that can reduce its effect. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential need effective contraception during treatment (acenocoumarol SmPC, AEMPS). Emergency contraception does not prevent pregnancy in every case and does not replace a regular method. If the period is more than 5 days late or the bleeding at the expected time is unusual, rule out pregnancy with a test (levonorgestrel SmPC, AEMPS). Use a barrier method until the next menstrual cycle starts. Repeated use within one cycle is not recommended (levonorgestrel SmPC, AEMPS). Consider the possibility of thromboembolism in women with other thromboembolic risk factors, especially a personal or family history suggesting thrombophilia (levonorgestrel SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol